HCW Biologics Inc. (NASDAQ:HCWB) Sees Significant Decrease in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 37,709 shares, a decrease of 38.1% from the September 30th total of 60,941 shares. Currently, 1.9% of the shares of the company are short sold. Based on an average daily trading volume, of 226,124 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analyst Weigh In

Several brokerages recently commented on HCWB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, October 15th. Wall Street Zen upgraded HCW Biologics from a “sell” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $30.00.

HCW Biologics Price Performance

HCWB opened at $1.15 on Wednesday. The company has a 50 day simple moving average of $1.88 and a two-hundred day simple moving average of $4.10. The firm has a market cap of $2.58 million, a P/E ratio of -0.04 and a beta of 2.31. HCW Biologics has a 1-year low of $1.09 and a 1-year high of $23.94.

HCW Biologics (NASDAQ:HCWB) last announced its quarterly earnings data on Friday, August 14th. The company reported ($11.58) EPS for the quarter, missing the consensus estimate of ($1.98) by ($9.60). HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%. The firm had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.14 million.

HCW Biologics Company Profile

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.

HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.